Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Ezutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and...

Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE...

Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress OXFORD, United Kingdom, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...